Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.36 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408912 | 0.82 | LPL (0.39) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL2408911 | 0.82 | LPL (0.39) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL2406622 | 0.80 | LPL (0.48) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL7604498 | 0.80 | AGXT (0.44) | CA2CA1KMT2A | |
| SCHEMBL1013889 | 0.78 | IDO1 (0.42) | CA2CA1KMT2AHTT | |
| SCHEMBL556155 | 0.78 | IDO1 (0.42) | CA2CA1KMT2AHTT | |
| SCHEMBL7863791 | 0.78 | TSHR (0.52) | CA2CA1KMT2AHTT | |
| SCHEMBL4545488 | 0.78 | TSHR (0.52) | CA2CA1KMT2AHTT | |
| SCHEMBL13002270 | 0.78 | TSHR (0.52) | CA2CA1KMT2AHTT | |
| SCHEMBL104085 | 0.77 | LPL (0.58) | LPLLIPGCA2CA1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG | 2010-10-07 | — | — | US | disclosed |
| EP-2212317-A1 | 4,4-DISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212315-A1 | TRISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053452-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009050253-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | LPL 2373/4885LIPG 1550/4885CA2 510/4885 |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | REN, AGTR1, AGTR2 | LPL 3316/4885LIPG 2310/4885CA2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.